Oxford BioDynamics subsidiary signs exclusive Asia licence for breast cancer test

Oxford BioDynamics subsidiary signs exclusive Asia licence for breast cancer test

May 18, 2017 Off By Dino Mustafić

Oxford BioDynamics’s subsidiary Oxford BioDynamics Pte Limited, has signed an exclusive licence agreement with Nova Satra Diagnostics Asia Limited, to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia.

Specifically for Malaysia, Oxford BioDynamics has granted its consent for NSDA to grant an exclusive sub-licence to Genting Laboratory Services Sdn Bhd, a wholly owned subsidiary of Genting Berhad, to provide the proprietary breast cancer test.

NSDA is a wholly owned subsidiary of Nova Satra Dx Pte Ltd., a Singaporean company that develops and commercialises blood-based diagnostic tests to provide the early detection of cancer. Nova Satra Dx. is an associate company of Genting Berhad, a Malaysian conglomerate.

According to the agreement, the Licence exclusively grants NSDA the right to use Oxford BioDynamics’ proprietary products and reagents, provided through the Company’s EpiSwitch technology platform, for breast cancer patients stratification. NSDA will be solely responsible for completing the regulatory approval process and commercialisation activities of the breast cancer test within 13 territories in Asia. In return, Oxford BioDynamics will receive an upfront licensing payment, royalties on sales of the test and fees on the achievement of certain material undisclosed milestones.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said: “Our proprietary EpiSwitch technology will be instrumental in the development of this novel blood-based test that will assist in the diagnosis of breast cancer in the Asian population. This latest EpiSwitchTM licence agreement will generate royalty and milestone fees for the Company. This agreement further demonstrates the broad application potential of OBD’s technology.”